Switching to integrase strand transfer inhibitors (INSTI) from protease inhibitors is associated with new diabetes risk in people with HIV.

Switching to INSTI-based ART from protease inhibitors is associated with an increased risk for incident diabetes in treatment-experienced adults.

Diabetes mellitus affects more than 10% of people with HIV, and its incidence is rising as the population ages, according to the National Institutes of Health. Antiretroviral therapies that treat HIV ...

Weight gain associated with integrase strand transfer inhibitor-based antiretroviral therapy (ART) may be mitigated or reversed over time by switching to protease inhibitor-based ART. For patients ...

Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.

HIV-1 protease is a critical enzyme in the viral life cycle, facilitating the maturation of infectious viral particles by cleaving precursor polyproteins. The emergence of drug resistance, driven by ...

Proteases are naturally-produced enzymes your body needs for digestion and blood clotting. Most people make enough proteases, but supplements can help if you have certain health conditions. Pineapples ...